The trial by Stevinson et al. 1 was designed as a preliminary investigation but was analysed and reported as if it were a definitive trial.
The placebo group required 45% more postoperative analgesia than one of the verum groups (arnica 6C), a result which, if confirmed, is certainly clinically relevant. This verum group also had lower pain scores and, of course, these two variables are inversely related (i.e. for the same underlying pain level, patients taking more analgesia will report lower pain scores than those taking less). Analysing these variables separately therefore underestimates the effect size-in this case, the pain-reducing effect of arnica 6C. This goes unremarked in the paper.
The CONSORT statement on the reporting of randomized trials calls for reporting of estimates of precision (95% confidence intervals), stating that 'They are especially valuable in relation to non-significant differences, for which they often indicate that the result does not rule out an important clinical difference'. 2 Regrettably, Stevinson et al. do not report confidence intervals, and their trial came nowhere close to detecting statistical significance for the clinically very significant lower analgesia requirements in one of the active treatment groups.
In a preliminary investigation absence of proof should not be misinterpreted as proof of absence. By analysing the study as a definitive trial, the authors drew conclusions that it was not capable of delivering. Viewed as a feasibility study, it suggests that arnica 6C may be associated with useful benefits in terms of postoperative pain, a conclusion that accords with another published study. 3 It could inform a larger study, including a sample size calculation, outcome measures and their timing.
If we do another arnica trial we certainly will (and others intending independent replications should) do a retrospective power calculation based on the data of our trial. We felt that it would have added little to the present study 1 and also were very strapped for space.
Our study was an offshoot of a systematic review of all placebo-controlled trials of homeopathic arnica. 2 This analysis included 8 such studies and concluded that 'the claim that homeopathic Arnica is efficacious beyond a placebo effect is not supported by rigorous clinical trials'. 2 German homeopaths later replicated this review and reluctantly conceded that 'efficacy . . . must be interpreted with utmost care'. 3 I therefore feel that the results of our trial, which incidentally had a larger sample size than any previous arnica study, have to be seen in the context of previous research.
Dr Richardson refers to 'poor adherence'. In the actual article, we discuss why we feel reasonably certain that suboptimal adherence did not relevantly influence our results. A 'per protocol' analysis of our data would not have altered our principal finding. The fact that we don't mention exclusion of outliers obviously means that we did not exclude outliers. She suggests comparison of patient characteristics using statistical analysis, but this is not a legitimate approach. Clinical trials are not designed to test the hypothesis that two treatment groups are statistically different. Thus applying test statistics to this particular question is strictly speaking a misuse of statistics. Reviewing the baseline values in some detail, I find no reason to believe that the two groups were relevantly different or that the small existing differences influenced the result. It is true that in our article the use of rescue medication was only presented in a global fashion. More detailed analyses, we felt, were not justified as this was not a primary outcome measure. Reviewing these data in more detail, I see no reason to suspect that this confounded the results.
Dr Hughes-Games states that 'patients taking arnica 6C needed fewer painkillers'. This is not true. Our results show that they required an amount which was not statistically different from that of the other two groups. This commentator also believes our study was too small and then tells us anecdotes from his own clinical practice. Is a randomized trial of 62 patients really less conclusive than single case reports? I agree with Hughes-Games that it would be tragic to discard an effective treatment because of scientists' disbelief. But what about continuing to use an ineffective treatment because of homeopathic belief? The weight of the evidence 1-3 strongly suggests that the latter is what we have been witnessing.
Dr Lewith makes several points which are easy to clarify. Ours was not, of course, a proving study but a therapeutic trial. We used two different doses (30C and 6C), thus his argument about a 'proving dose' does not really apply. The fact that some (by no means all) provings used a 30C dose certainly does not mean that 30C is not used therapeutically. We determined the two doses through consultations with homeopaths, and I am a trained homeopath myself. I therefore see neither the 'oversight' nor the 'methodological flaw' which Lewith points out. To imply that we neglected the principles of homeopathic practice can only be based on a lack of understanding of our study: in everyday homeopathic practice arnica is used in acute prescribing for tissue trauma, and this was the basis of our hypothesis.
Dr Matthews argues that NNT could have been used for a sample size calculation to determine a 'worthwhile' effect. In hindsight this makes sense to me, even though we would not have had the funds for a trial with 200 patients. Matthews also mentions that our trial could be valuable for a systematic review. I agree, and would add that the effect would be to make the findings from the two existing reviews 2,3 even less encouraging than they already are.
Dr Fisher and his colleagues, in voicing suspicion that our trial was underpowered, cite a further trial (sample size=37) in support of their belief that, homeopathic arnica is, after all, effective. 4 The cited study, however, was a trial not of homeopathic arnica alone but of arnica in combination with a herbal cream applied topically. The conclusion of our paper was, 'The results of this trial do not suggest that homeopathic arnica has an advantage over placebo in reducing postoperative pain, bruising and swelling in patients undergoing elective hand surgery'. I fail to see how we confused 'absence of proof' with 'proof of absence'. how things come to be and provided a mechanism for reasoning that could be applied to any academic discipline. In modern times, when medicine is threatened by information-overload, the philosophical process (inquiry, critical reasoning, analysis) can offer valuable insights for practice. However, as Dr Harper indicates, acceptance demands an end to the misconception that philosophy is incompatible with practical science. The general view is that, while science has answers that command widespread agreement, philosophy is interested in matters on which there is less consensus. By challenging concepts and assumptions, the philosophical approach can generate new perspectives in science. Advances in genomic biotechnology, for instance, illustrate the difficulty of deciding what to do with scientific discoveries. We need to consider what society we wish to have and our relationships with each other and our surroundings, which depend on our conception of ourselves as human beings at societal level. This is where, in our opinion, Dr Harper's article is overambitious in scope. In trying to cover a large area, he omits certain issues that are important in explicating/ exploring the common ground between philosophy and medicine; for example, how should ethics be applied in the medical arena, or how does morality ethically connect with human society? His choice of philosophers was necessarily limited, but in an article about science as applied to medicine we would have included the following: Thales of Miletus, the first natural scientist and analytical philosopher in Western intellectual history; Aristotle, for his observation, methodological classification and empirical analysis; Bertrand Russell, for his logical analysis; 2 and Michel Foucault, for his insightful analysis of scientific knowledge and social control. 3 
